According to WHO, an estimated 700,000 people die each year worldwide from bacterial infections, including an estimated 23,000 people in the United States. Since BARDA founded CARB-X in 2016, this public-private partnership has become the world’s largest dedicated to early development of novel products to combat antibiotic resistant infections. To date, CARB-X has invested more than $150 million to accelerate the development of antibiotics, vaccines, diagnostics and other life-saving products to combat drug-resistant superbugs. “Antibiotic resistance is a real and serious threat to national security and public health,” said Rick Bright, PhD, HHS Deputy Assistant Secretary for Preparedness and Response and Director of BARDA. “CARB-X has generated valuable momentum in re-catalyzing the antibiotic pipeline. Reaching this milestone of supporting 50 innovative candidates in just three years is a testament to what can be achieved through public-private partnerships and to the power of diverse international coalitions working together to manage this urgent problem.”